Prosight Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Prosight Management’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-709	Closed	-$68K	–	42
2019 Q1	$68K	Buy	+709	New	+$63.6K	0.03%	38

Other funds holding ENTA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Prosight Management's ENTA Position: Q2 2019 in Review

Prosight Management sold out of Enanta Pharmaceuticals (ENTA) in Q2 2019, closing a stake of 709 shares — an estimated $68K sold.

Prosight Management first reported a position in ENTA in Q1 2019 and held it in 1 quarter. The position peaked at $68K in Q1 2019. 194 funds tracked by Wall St. Rank hold ENTA as of Q2 2019.

Prosight Management reported no remaining Enanta Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Prosight Management sold 709 Enanta Pharmaceuticals shares in Q2 2019, an estimated $68K.
Prosight Management first reported a position in Enanta Pharmaceuticals in Q1 2019 and held it in 1 quarter.
Prosight Management's Enanta Pharmaceuticals position peaked at $68K in Q1 2019.
194 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2019.

Based on Prosight Management's 13F filing for Q2 2019, filed 14 Aug 2019.